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Multiancestry association study identifies new asthma risk loci 
that colocalize with immune cell enhancer marks
A full list of authors and affiliations appears at the end of the article.
Abstract
We examined common variation in asthma risk by conducting a meta-analysis of worldwide 
asthma genome-wide association studies (23,948 cases, 118,538 controls) from ethnically-diverse 
populations. We identified five new asthma loci, uncovered two additional novel associations at 
two known asthma loci, established asthma associations at two loci implicated previously in 
comorbidity of asthma plus hay fever, and confirmed nine known loci. Investigation of pleiotropy 
showed large overlaps in genetic variants with autoimmune and inflammatory diseases. 
Enrichment of asthma risk loci in enhancer marks, especially in immune cells, suggests a major 
role of these loci in the regulation of immune-related mechanisms.
Asthma is a complex disease affecting hundreds of millions of people worldwide. Asthma 
prevalence varies between populations and ethnicities, ranging in the U.S. from 3.9% in 
Mexican Americans to 12.5% in African Americans1. The contribution of genetic factors to 
asthma risk has been demonstrated in family studies, where heritability estimates range from 
25%-80%2. The large variability in prevalence and heritability estimates reflects the role of 
environmental exposures on disease risk and phenotypic heterogeneity that are hallmarks of 
asthma. These features may explain why genome-wide association studies (GWAS) have 
uncovered a smaller number of asthma loci than similarly sized studies of other 
multifactorial diseases3. Indeed, at the time of analysis, only 21 loci have been associated 
with asthma per se in 20 studies, and these loci explain only part of the genetic risk. 
Although an exome-chip study showed no evidence for low frequency or rare variants with 
large effects on asthma risk4, the role of noncoding rare variants in asthma remains 
unknown. Future studies based on whole-genome sequencing may clarify the respective 
influence of common and rare variants on asthma risk. To generate larger sample sizes for 
GWAS meta-analysis of asthma enabling the discovery of common novel risk loci, we 
established the Trans-National Asthma Genetic Consortium (TAGC) across worldwide 
groups of investigators with genome-wide data available in >142,000 individuals of diverse 
ancestries. We constructed a comprehensive catalog of asthma risk variants that are robust 
across populations and environmental exposures. By combining TAGC meta-analysis results 
with existing databases, we assessed the genetic architecture of asthma risk alleles with 
respect to functional effects and shared effects with other diseases.
The authors who are affiliated with deCODE (D.F.G., I.J., K.S., U.T., G.T.) are employees of deCODE genetics/AMGEN. All other 
co-authors did not declare any conflict of interest
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RESULTS
Meta-analysis of asthma GWAS
We combined data from asthma GWAS with high-density genotyped and imputed SNP data 
(2.83 million SNPs) in the following populations: European-ancestry (19,954 cases, 107,715 
controls), African-ancestry (2,149 cases, 6,055 controls), Japanese (1,239 cases, 3,976 
controls) and Latino (606 cases, 792 controls) (Supplementary Table 1). After extensive QC 
of summary data provided by each participating group (Online Methods, Supplementary 
Note and Supplementary Table 2), we first conducted ancestry-specific meta-analyses 
followed by a multi-ancestry meta-analysis of all populations (23,948 cases, 118,538 
controls) to identify additional loci with pan-ancestry effects. Because childhood-onset 
asthma may be distinct from later-onset asthma5 and may represent a more homogeneous 
subgroup, we also performed analyses on the pediatric subgroup (asthma onset ≤16 years; 
8,976 cases, 18,399 controls). Meta-analyses of SNP effect sizes obtained from each asthma 
GWAS were performed using fixed-effects (significance of the combined SNP effect size 
summarized in Pfixed) and random-effects (Prandom) models (Online Methods) and using a 
conventional Prandom (or Pfixed) threshold of 5×10−8 to define genome-wide significance. 
Results were consistent between methods for detecting loci with at least one SNP 
significantly associated with asthma. We therefore present the results from the random-
effects analysis for the European-ancestry and multi-ancestry meta-analyses, which include 
the largest number of studies and allow an accurate estimate of the between-study variance, 
and results from the fixed-effects analysis for the African-ancestry, Japanese and Latino 
meta-analyses. We observed little evidence of inflation in the test statistics in either the 
ancestry-specific (lambda: European-ancestry, 1.031; African-ancestry, 1.014; Japanese, 
1.021; Latino, 1.044) or multi-ancestry (lambda=1.046) meta-analyses (Supplementary Fig. 
1).
We identified 673 genome-wide significant SNPs (Prandom≤5×10−8) at 16 loci in European-
ancestry populations (Fig. 1a, Table 1, Supplementary Tables 3 and 4; Online Methods for 
locus definition). No genome-wide significant risk loci were detected in African-ancestry, 
Japanese or Latino populations (Supplementary Fig. 2 and Supplementary Tables 5–7), 
possibly due to a lack of power. In the combined multi-ancestry meta-analysis, 205 
additional SNPs were significant at Prandom≤5×10−8, including 12 SNPs at two loci not 
detected in the European-ancestry analysis (Fig. 1b, Table 1, and Supplementary Tables 3 
and 8). Altogether, 878 SNPs at 18 loci reached genome-wide significance, of which 69% 
were significant in both European-ancestry and multi-ancestry meta-analyses, 23% were 
significant in the multi-ancestry meta-analysis only, and 8% were significant in the 
European-ancestry meta-analysis only (Supplementary Tables 4 and 8 and Supplementary 
Fig. 3 for the regional plots of the 18 loci). All 18 loci remained genome-wide significant 
after further genomic control correction of the test statistics, confirming the robustness of 
these results (Supplementary Table 9).
The 18 chromosomal regions included five new loci associated with asthma at 5q31.3, 
6p22.1, 6q15, 12q13.3, 17q21.33; two new associations at 6p21.33 and 10p14 that were 
independent from previously reported signals at these loci in ancestry-specific populations 
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(Latino6 and Japanese7, respectively); two associations at 8q21.13 and 16p13.13 that were 
previously reported for asthma plus hay fever but not for asthma alone in a study of 
European-ancestry populations8; and nine previously identified asthma loci.
None of the lead SNPs at the 18 loci showed evidence for heterogeneity in effect sizes across 
studies except for the lead variant at 9p24.1 (Phet for Cochran’s Q test9=0.008 across 
European-ancestry studies and Phet=0.02 across multi-ancestry studies, Table 1, 
Supplementary Fig. 4). There was also significant evidence for heterogeneity in ancestry-
specific effect sizes (Pethnic =0.003) for the 6p22.1 lead SNP rs1233578, which, 
consequently, did not reach significance in the multi-ancestry analysis (Table 1, 
Supplementary Table 3). The meta-analysis of the pediatric subgroup showed evidence for 
association (Prandom≤5×10−8) at five of the 18 loci (2q12, 5q31, 6p21.33 9p24.1 and 17q12–
21) (Supplementary Figs. 5 and 6 and Supplementary Table 10). No loci specific to that 
group were identified.
The results provided genome-wide significant confirmation of nine previously reported loci 
in both European-ancestry and multi-ancestry meta-analyses (Table 1; Supplementary Figs. 
3b and 4). Our results allow detailed analysis of the broad 17q12–21 locus. It is notable that 
the lead SNP (rs2952156) at this locus is within ERBB2 (Prandom=2.2×10−30 in multi-
ancestry meta-analysis), at least 180 kb from the previously recognized asthma-associated 
signals at the GSDMB/ORMDL3 haplotype block3 (Supplementary Fig. 7). This is 
attributable to effect size heterogeneity across studies (0.001≤Phet≤0.05) that extends over a 
200 kb region that includes ORMDL3 and GSDMB (Supplementary Table 11). This 
heterogeneity is partly due to age of asthma onset, as previously reported5. Indeed, in the 
pediatric group, the 17q12–21 SNPs did not show heterogeneity (Phet≥0.09) and the lead 
SNP rs8069176 is 3.6 kb proximal to GSDMB (Prandom=Pfixed=4.4 ×10−26), consistent with 
previous studies3,5. The SNP effect sizes in the pediatric and non-pediatric studies show a 
significant difference for rs8069176 at the GSDMB locus (Phet=7.4×10−4) but no difference 
for rs2952156 at the ERBB2 locus (Phet=0.11). These two SNPs are only in moderate LD 
(r2=0.30) and, interestingly, each is in strong LD (r2>0.9) with missense variants localized in 
ERBB2 for the proxy of rs2952156 and in ZPBP2 and GSDMB for the proxies of 
rs8069176. Moreover, both rs2952156 and rs8069176 are associated with GSDMB and 
ORMDL3 expression in blood e-QTL databases10–13 and with expression of GSDMA, 
CDK12, GSDMB, ORMDL3 in whole lung tissue12,14. However, only rs2952156 is 
associated with PGAP3 transcript in lung12,14 (Supplementary Table 12a). Further 
exploration of eQTL data from GTEx12 indicated that rs8069176 accounts for a large part of 
the association of the most significant SNP with ORMDL3 transcript in blood while 
rs2952156 accounts for a large part of the association of the most significant SNP with 
PGAP3 transcript in lung (Supplementary Table 12b), suggesting that the asthma-associated 
signals near PGAP3/ERBB2 and ORMDL3/GSDMB blocks may affect asthma risk through 
the expression of different genes in different tissues..
Finally, of the 21 published asthma loci, 12 did not reach genome-wide significance in 
TAGC (Supplementary Table 13). The most significant SNPs in the GWAS catalog3 at seven 
of those loci had P-values>0.01 in TAGC analyses. Among these seven non-replicated loci, 
two (4q31.217, 8q24.1115) were reported in Japanese, three (4q12, 9p23, 10q24.2)16 had 
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SNPs with low minor allele frequencies (≤ 2%) and were reported in a childhood-onset 
asthma study, and two (1q31.317, 5q12.118) were reported in European-ancestry children 
with asthma defined by current or persistent asthma symptoms with regular use of 
medication. The most significant SNPs at the remaining five loci had P-values ≤5×10−4 in at 
least one TAGC meta-analysis, thus providing some replication. Amongst these five loci, the 
1q23.1 locus is specific to African-ancestry populations19; the 12q13.2 SNP, reported by a 
Japanese study7, showed heterogeneity in the TAGC Japanese meta-analysis as well as in 
European-ancestry and multi-ancestry meta-analyses (Phet ≤0.05); and the 7q22.3 SNP, 
reported in European-ancestry populations20, was associated with a severe form of 
childhood asthma and also showed heterogeneity across studies in the original publication20 
(where the Prandom value did not reach significance) as well as in our study (European-
ancestry, multi-ancestry and pediatric meta-analyses, 0.006≤Phet≤0.03). Finally, SNPs at 
1q21.3 and 22q12.3 loci, previously reported in European-ancestry populations21,22, did not 
show significant evidence for heterogeneity across TAGC studies in the European-ancestry 
and multi-ancestry meta-analyses (0.11≤Phet≤0.19). When we repeated these two meta-
analyses, under a fixed-effects model and considering separately the set of TAGC datasets 
that were part of the original publication (set P) and the set of remaining TAGC datasets (set 
R), both 1q21.3 and 22q12.3 SNPs had higher effect sizes in set P than in set R. These 
differences in effect sizes did not reach significance for the 1q21.3 SNP (Phet for Cochran’s 
Q test are 0.13 and 0.20 in European-ancestry and multi-ancestry analyses) and were 
borderline significant for the 22q12.3 SNP (0.04≤Phet≤0.06) (Supplementary Table 14). 
Altogether, these results suggest that the lack of replication is mainly due to heterogeneity 
that is attributable to various factors, such as ethnicity, specificity of clinical phenotypes or 
other factors as further discussed.
To investigate whether the 18 asthma loci identified in this study contain multiple distinct 
signals, we performed approximate conditional regression analysis based on summary 
statistics for all loci (Online Methods), except for the 9p24.1 region which showed 
heterogeneity in SNP effect size across studies over the whole locus. For the 17q12–21 
locus, this analysis was restricted to the pediatric sub-group in which there was no 
heterogeneity. After conditioning on the lead SNP in each investigated region, four 
secondary signals (2q12, 5q22.1, 5q31, 6p21.32) remained significant (Pfixed≤5×10−8) 
(Supplementary Table 15), yielding 22 distinct genome-wide significant signals.
To provide biological insight into our findings, we conducted a comprehensive bioinformatic 
assessment of the asthma association signals. To pinpoint the most likely candidate genes at 
the nine loci harboring novel associations with asthma per se, we interrogated results of six 
eQTL studies in tissues relevant to asthma, blood (including peripheral blood11,12, 
lymphoblastoid cell lines (LCLs)10,13, monocytes23) and whole lung tissue12,14, and 
searched for missense variants potentially tagged by the association signals. To assess the 
level of overlap of asthma associations with susceptibility loci for other phenotypes, we 
interrogated the GWAS catalog3 while varying the strength of association with asthma 
(thresholds from 5×10−8 to 10−3). To get greater insight into how asthma associated variants 
may functionally influence disease, we interrogated the ROADMAP/ENCODE functional 
genomics data generated in a wide range of human cell types24. Finally, the degree of 
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connectivity between the asthma-associated loci was assessed through text mining25. Results 
are described below.
Candidate genes at the nine loci showing novel associations
A summary of eQTL analysis for these nine loci is described in Table 2 and Supplementary 
Table 16; regional plots are shown in Supplementary Fig. 3a.
New asthma susceptibility loci—Five new loci were identified in this study. The 
strongest new signal in both the European-ancestry (Prandom=8.6×10−13) and multi-ancestry 
(Prandom=2.2×10−12) meta-analyses was with SNP rs2325291 in an intron of BACH2 at 
6q15, which is strongly correlated with rs10455168 (r2=0.91), a cis-eQTL altering 
expression of BACH2 in blood11. BACH2 encodes a zip transcription factor that regulates 
nucleic acid-triggered antiviral responses in human cells26. The second strongest signal in 
the European-ancestry and multi-ancestry analyses was with rs17637472 (Prandom=3.3×10−9 
and 6.6×10−9), which lies between ZNF652 and PHB at 17q21.33, and is a strong cis-eQTL 
for GNGT2 (173 kb from rs17637472) in blood10,11,13,23. GNGT2 interacts with beta-
arrestin 1 to promote G-protein-dependent Akt signaling for NF-kappaB activation27.
Among the other new signals, the lead SNP rs1233578 at 6p22.1 (Prandom=5.3×10−9 in 
European-ancestry populations) resides between TRIM27 and GPX5. This SNP was not 
associated with gene expression in blood or lung but is in LD (r2=0.6 in European-ancestry 
populations) with rs7766356 (312 kb from rs1233578), which is a cis-eQTL for ZSCAN12 
in blood13 and ZSCAN31 in lung14. These zinc finger protein encoding genes were 
associated with lung function28. The two SNPs, rs1233578 and rs7766356, represent the 
same association signal in European-ancestry populations (the association with rs7766356 
becomes non-significant after conditioning on the lead SNP rs1233578). The 12q13.3 lead 
SNP (rs167769), which was only significant in the multi-ancestry analysis 
(Prandom=3.9×10−9), lies in an intron of STAT6 and is strongly associated with STAT6 
expression in blood10,11,13 and lung14. STAT6 is a transcription factor, essential for the 
functional responses of Th2 lymphocytes mediated by IL-4 and IL-1329. This result robustly 
establishes the association of STAT6 with asthma risk that has been disputed by candidate 
gene studies30. The 5q31.3 lead SNP rs7705042 (Prandom=7.9×10−9 in multi-ancestry 
analysis) is within an intron of NDFIP1 and associated with NDFIP1 expression in 
blood11–13. NDFIP1 is a potent inhibitor of antiviral response31 and inflammation 
processes32.
New asthma signals at loci reported in specific populations—Two associations in 
our study were with novel SNPs at loci previously reported to be associated with asthma in 
Latinos6 and Japanese7. The first one at 6p21.33 was reported in an admixture mapping 
study in Latinos6. The lead TAGC SNP, rs2855812 (Prandom=8.9×10−12 in the multi-ancestry 
analysis, Prandom =1.7×10−8 in the European-ancestry meta-analysis) lies in an intron of 
MICB. This SNP was not correlated (r2=0) with any of the SNPs reported in the Latino 
study6. The 6p21.33 region harbors many genes whose transcripts are associated with TAGC 
asthma signals, including TNF, LST1, HLA-C, LTA in blood10,11,13 and MICB in lung12,14. 
These genes are involved in immune-related mechanisms. This 6p21.33 locus is about 600 
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kb apart from the previously reported 6p21.32 locus that spans HLA-Class II genes. 
Intensive sequencing efforts will be needed to further clarify the HLA region associations. 
The second association was at 10p14 locus where a GWAS in Japanese7 reported association 
(lead SNP rs10508372) with adult asthma. We detected a new signal, rs2589561, in 
European-ancestry (Prandom=1.4×10−8) and multi-ancestry meta-analyses 
(Prandom=3.5×10−9), that is not correlated with rs10508372 in either European-ancestry or 
Japanese populations. The SNP rs2589561 is in a gene desert, 929 kb distal of GATA3. 
However, recently published promoter capture Hi-C data in hematopoietic cells33 revealed 
that two proxies of rs2589561 (r2>0.9) lie in a region that interacts with the GATA3 
promoter, especially in CD4+T cells. This suggests that the SNP may be in a distal regulator 
of GATA3, which encodes a transcription factor that is a master regulator of differentiation 
of Th2 cells and innate lymphoid cells type 234.
Asthma signals reported for asthma plus hay fever—Loci on chromosomes 
8q21.13 and 16p13.13 were previously associated with asthma plus hay fever but not with 
asthma alone in one European-ancestry study8. In our results, the 8q21.13 lead SNP 
rs12543811 (Prandom=3.4×10−8 and 1.1×10−10 in the European-ancestry and multi-ancestry 
analyses) lies between TPD52 and ZBTB10 and is in strong LD (r2=0.79) with the 
previously reported asthma/hay fever SNP rs7009110. These two SNPs represent the same 
signal, as the association with rs12543811 becomes non-significant after conditioning on 
rs7009110. Thus, the 8q21.13 locus is likely implicated in allergic asthma. A functional 
analysis of the asthma/hay fever locus pinpointed PAG1 as a promising candidate35. The 
chromosome 16p13.13 SNP rs17806299 is within an intron of CLEC16A 
(Prandom=2.1×10−10 and 2.7×10−10 in European-ancestry and multi-ancestry meta-analyses). 
Although in moderate LD (r2=0.66) with the previously reported asthma/hay fever signal 
(rs62026376)8, the association of asthma with rs17806299 was removed after conditioning 
on rs12935657 (r2=0.96 with rs62026376), indicating that these SNPs represent the same 
signal and 16p13.13 is probably also an allergic asthma locus. The SNP rs17806299 is 
strongly associated with the expression of a nearby gene, DEXI in blood11,23. Similar 
observations of associations of CLEC16A SNPs with autoimmune diseases and expression 
of DEXI together with chromosome conformation capture experiments implicated DEXI as 
the most likely candidate gene for autoimmune diseases36. The potential relevance of DEXI 
in allergic diseases has also been previously discussed8.
It is notable that the lead SNPs at the nine new asthma-associated loci lie in non-coding 
regions and are not tagging missense variants.
Overlap of loci associated with asthma and other phenotypes
We next explored whether the nine loci that harbored new signals for asthma per se 
overlapped with GWAS loci reported for allergy-related phenotypes, lung function 
phenotypes, or other immune-related diseases using the GWAS catalog3. Six of these nine 
asthma loci showed overlapping associations with allergy-related phenotypes and eight of 
them with auto-immune diseases or infection-related phenotypes (Table 2). Moreover, three 
asthma loci overlapped with associations with lung function phenotypes.
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We expanded our search of overlap between the asthma association signals having multi-
ancestry Prandom<10−4 in this study and GWAS signals with all phenotypes and diseases in 
the GWAS catalog3. We examined 4,231 unique trait-loci combinations (Online Methods), 
and used the disease classification from Wang et al.37 to group traits. We summarized the 
overlap with GWAS catalog signals as the proportion of catalog SNPs having asthma P-
values<10−4 in our analysis. This revealed significant overlap with autoimmune disease 
(10%, i.e. 49 out of 480 catalog SNPs show evidence for asthma association), consistent 
with the hypothesized shared susceptibility38,39, moderate overlap with diseases having an 
inflammatory component (cardiovascular diseases, cancers, neuro-psychiatric diseases), and 
small to no overlap with other diseases (Table 3). When investigating specific diseases and 
traits (Supplementary Table 17), the most significant overlap is with allergic phenotypes. 
There is little to no overlap with other phenotypes that appear most frequent in the GWAS 
catalog (for example, no shared associations with type 2 diabetes).
When we broadened our analysis to a larger set of SNPs in the GWAS catalog to identify 
loci for diseases with potentially shared genetic architecture with asthma (i.e, SNPs 
associated with asthma at Prandom≤10−3 in our multi-ancestry meta-analysis), additional 
pleiotropic signals emerged (Supplementary Table 18). This larger set of associations 
suggests a broader picture of asthma risk, with a wide range of pleiotropic effects for traits 
ranging from lung cancer and multiple sclerosis (with rs3817963 in BTNL2) to coronary 
heart disease (with rs1333042 near CDKN2B). This analysis also generated an extended set 
of asthma candidate genes. Indeed, there are 210 SNPs in the GWAS catalog that are 
associated with asthma in TAGC at a threshold of 10−3; the proportion of false positives 
among these is smaller than 1%.
Enrichment of asthma risk loci in epigenetic marks
Because nearly all lead SNPs at the 18 loci identified by this study lie in non-coding 
sequences, except for the IL13 missense variant (rs20541), we investigated whether the 
asthma-associated variants and their proxies (r2≥0.80) were concentrated in cis-regulatory 
DNA elements. Only 16 of 18 identified asthma loci were explored because we excluded the 
two loci spanning the HLA region due to the large amount of variability and extensive LD in 
this region. We interrogated the 111 ROADMAP and 16 ENCODE reference epigenomes in 
a wide range of human cell types24. We focused on histone marks characterizing enhancers 
and promoters assayed in all 127 epigenomes and DNase I-hypersensitive sites available in 
51 cell types. To assess enrichment of the asthma risk variants for co-localization with these 
regulatory elements, we used the Uncovering Enrichment through Simulation pipeline40. 
This approach generates random SNP sets that match the characteristics of the original 
asthma-associated SNPs (distance from the nearest transcription start site, number of LD 
partners, minor allele frequency). Empirical P-values for enrichment are calculated by 
comparing the observed frequency of co-localization of SNPs with a given type of 
regulatory element in the original asthma-associated SNP set to the co-localization 
frequency distribution obtained from the 10,000 random SNP sets generated. Benjamini-
Hochberg false discovery rates (FDRs) are then computed to correct for multiple testing 
(Online Methods).
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While the asthma-associated variants were strongly enriched for co-localization with 
enhancer marks, there was only weak enrichment in promoter marks (Table 4 and 
Supplementary Table 19). This enrichment was highest in leukocytes (27 leukocytes of 
which 19 (70%) are lymphocytes and monocytes). For example, a FDR≤5% for enrichment 
of asthma loci in active enhancers was observed in 100% of leukocytes compared to 50% of 
all cell types. The enrichment of asthma risk variants for co-localization with DNase I-
hypersensitive sites was intermediate between the enrichments in promoters and enhancers 
and was again increased in blood cells (FDR≤5% in 40% of leukocytes and 12% of all cell 
types) (Table 4 and Supplementary Table 20).
The strong enrichment of asthma loci in enhancer marks, especially in immune cells, 
indicates that the associated genetic variants are likely involved in regulation of immune-
related functions. This also suggests that epigenetic mechanisms may be key to promoting 
asthma, as evidenced for IgE levels, an asthma-associated phenotype41.
Connectivity between asthma-associated loci
To characterize the degree of connectivity between the 18 asthma-associated loci, we applied 
the Gene Relationships Across Implicated Loci (GRAIL) text-mining approach25. Genes at 
eleven of these loci showed connections with a GRAIL score, PGRAIL, less than 5% (7 of 
them being highly connected with PGRAIL<10−3) (Fig. 2 and Supplementary Table 21). 
These genes were connected by keywords such as ‘asthma’, ‘allergy’, ‘atopic’, ‘interleukin’, 
‘cytokines’, ‘airway’, and ‘inflammation’, confirming the central role of immune-related 
mechanisms accounting for these connections.
DISCUSSION
In this meta-analysis of worldwide asthma GWAS in ethnically-diverse subjects, we 
discovered nine novel loci influencing asthma risk. This study confirms that immune-related 
mechanisms are prominent in asthma susceptibility and brings novel insights that open new 
routes for future asthma research. The asthma-associated loci identified by TAGC are 
enriched in enhancer marks and are likely to be involved in gene regulation. Although this 
was observed in immune cells, asthma genes (e.g., IL1RL1, TSLP, IL33, ORMDL3/
GSDMB) are also expressed in the airway epithelium where they modulate airway 
inflammation. Investigation of epigenetic marks in airway epithelial cells may bring 
additional insight. The best candidates at many loci are involved in immune response to 
viruses or bacteria, which underlines the importance of infections in asthma risk. This study 
further provides evidence for overlap of asthma loci with loci underlying auto-immune 
diseases and other diseases that have an inflammatory component, which strengthens the 
growing importance of pleiotropy in multifactorial diseases.
Our meta-analysis doubles the number of cases from prior genome-wide studies at the time 
of analysis21,22. We identified 878 SNPs that correspond to 22 distinct association signals at 
18 loci meeting criteria for genome-wide significance in European-ancestry and/or multi-
ancestry populations. Pooling data from ethnically-diverse populations can increase power to 
detect new loci (two loci reached the genome-wide threshold only in the multi-ancestry 
analysis) but may also increase heterogeneity. Besides differences in the genetic background, 
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varying environmental exposures can modify genetic risks and result in heterogeneity in 
SNP effect size, and consequently reduce power of multi-ancestry analysis compared to 
ancestry-specific analysis. Assuming an asthma prevalence of 10%, the variance in liability 
to asthma explained by the 22 genome-wide significant variants of this study was estimated 
to be 3.5% (95% Confidence Interval : 2.0%–5.4%) of which 72% was accounted for by the 
known loci and 28% by the new loci. It is of note that the current study was based on 
HapMap2-imputed data which was shared within the TAGC consortium and thus allowed 
detection of associations with common genetic variants (MAF≥1%).
The overall relative paucity of asthma risk loci detected by large-scale GWAS compared to 
other common diseases may be due to the clinical heterogeneity of asthma and the important 
role of differing environmental exposures. It is recognized that asthma is not a single disease 
but that the syndrome varies based on many characteristics42, including age of asthma onset, 
the severity of disease, the type of cellular inflammatory infiltrates, occupational exposures 
and the varying response to treatment.. It is thus possible that additional asthma loci will be 
revealed by studies targeting more specific asthma sub-phenotypes and/or taking into 
account environmental exposures.
In conclusion, future discoveries might come by exploring more complex models of asthma 
phenotypes and through the joint analysis of asthma and other immune-mediated and 
inflammatory diseases. The central role of gene regulatory mechanisms highlighted by our 
study might prompt genome-wide explorations of the epigenome in immune cells and the 
respiratory epithelium while integrating information on genetic variation and environmental 
exposure histories.
ONLINE METHODS
GWAS Studies and Data Shared
All 66 genome-wide association studies that form the TAGC consortium are described in the 
Supplementary Note and summarized in Supplementary Table 1. These studies included 56 
studies of European-ancestry (19,954 cases, 107,715 controls), seven studies of African-
ancestry (2,149 cases, 6,055 controls), two Japanese studies (1,239 cases, 3,976 controls) 
and one Latino study (606 cases, 792 controls), making a total of 23,948 cases and 118,538 
controls. There were 27 studies including only childhood-onset asthma (defined as asthma 
diagnosed at or before 16 years of age) which allowed us analyzing separately a pediatric 
subgroup (8,976 cases, 18,399 controls). All subjects provided informed consent to 
participate in genetic studies and local ethics committees for each of the individual studies 
approved the study protocol. Definition of asthma was based on doctor’s diagnosis and/or 
standardized questionnaires (see Supplementary Note for details). The samples were 
genotyped on a variety of commercial arrays, detailed in the Supplementary Note and 
Supplementary Table 2. GWAS were performed on imputed SNP data that were generated 
using HapMap2 as reference panel and one of the commonly used imputation software 
(Supplementary Note and Supplementary Table 2). In each dataset, the effect of each 
individual SNP on asthma, assuming an additive genetic model, was estimated through a 
logistic regression-based approach and expressed in terms of a regression coefficient with its 
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standard error; the detailed methodology and software used for analysis by each study can 
be found in the Supplementary Note and Supplementary Table 2.
Imputation, quality control (including adjustments for population stratification) and analysis 
was done by each group independently and data on a predefined set of 3,952,683 autosomal 
SNPs was shared. These SNPs were those of the HapMap Phase 2, release 21 panel in 
subjects from European, Asian and African-ancestry that were filtered using SNP annotation 
from the build 37.3 of the reference sequence and dbSNP b135 (31,587 SNPs (0.8% of all 
SNPs) from previous annotations that showed discrepancies with the chosen annotation were 
deleted). The variables that were shared contained the study name, general information on 
SNPs (rs number, chromosome, position, alleles (baseline and effect alleles as used in the 
analysis by each study), SNP status (imputed or genotyped SNP and whether the SNP 
genotype or imputed value was used in computation), quality control (QC) indicators (call 
rate and P-value for Hardy-Weinberg (HW) equilibrium test for genotyped SNPs, software 
used for imputation and imputation quality score for imputed SNPs), allele frequencies in 
cases and controls and information on association statistics (regression coefficient for SNP 
effect, standard error of regression coefficient, Z scores, P-values associated with Z score 
statistic).
Quality control of shared data
For each SNP, the alleles on the HapMap2 template (reference and alternate alleles on the 
positive strand) were compared to the alleles (baseline and effect alleles) used in the analysis 
by each group. When necessary, the association variables (allele frequencies, regression 
coefficient for SNP effect, Z score) were swapped to match the reference/alternate alleles of 
the template. Data for each SNP showing any ambiguity or error in assignment to the 
template were set to missing. In addition, a number of QC checks were done regarding the 
name, format, range of possible values for all shared variables mentioned in the previous 
paragraph as well as consistency checks across variables. Any problem or inconsistency was 
corrected, otherwise the data for that SNP were set to missing. After this first stage of QC 
procedure, association statistics for at least one SNP in at least one study were available for 
2.83 million autosomal SNPs. Strict QC criteria were used for inclusion of a SNP in the 
analysis. When a SNP genotype was used in the study analysis, these criteria were: call rate 
≥99%, P-value for HW test ≥10−6 and minor allele frequency (MAF) ≥0.01 in both controls 
and cases. When a SNP imputed value was used in the analysis, the criteria were: imputation 
quality score ≥0.5 and MAF≥0.01 in both controls and cases. The distribution of the 
summary statistics (regression coefficient for SNP effect, standard error, Z score) of all 
SNPs passing QC was examined for each study; SNPs that still showed extreme Z scores (≥ 
7 or ≤−7) after QC were excluded.
Meta-analysis of asthma GWAS
We conducted fixed-effects meta-analysis with inverse variance weigthing and random-
effects meta-analysis using the Der Simonian and Laird43 estimator of the between-study 
variance when the meta-analyses included a large number of studies (European-ancestry, 
multi-ancestry and pediatric sub-group meta-analyses), which allows an accurate estimate of 
the between-study variance. We used a fixed-effects model for the meta-analyses of the 
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African-ancestry, Japanese and Latino populations.. For all these meta-analyses, we used the 
SNP regression coefficient and standard error from each study for which the SNP passed 
QC. All meta-analyses were done with Stata version 14.1 (Stata Corp., College Station, 
Texas, USA). To minimize the false-positive findings and to obtain robust results, we 
examined the combined results for SNPs for which at least two-thirds of the studies 
contributed to a meta-analysis. Tests of significance of the combined effect sizes were 
performed using a standard normal distribution. We applied a threshold of Prandom (or Pfixed) 
of 5×10−8 to declare a combined SNP effect as genome-wide significant. To verify the 
robustness of the results, we applied a genomic control correction to the association test 
statistics. The lead SNP at a locus was the variant with the strongest evidence for association 
in the European-ancestry or multi-ancestry meta-analysis. We defined a support interval 
around the lead SNP designated as “locus”; the bounds of this interval were the positions of 
the two most extreme SNPs among all SNPs lying within 500 kb on each side of the lead 
SNP and having Prandom (or Pfixed)≤10−6. Heterogeneity of per-SNP effect sizes across all 
studies in a meta-analysis was assessed using the Cochran’s Q test9. A difference between 
the four ethnic-specific summary effects was also tested with the Cochran’s Q statistic.
Conditional analysis of asthma-associated loci
The Genome-wide Complex Trait Analysis (GCTA) software44 (see URLs) was used to 
perform approximate conditional analysis for all loci with at least one SNP reaching the 
genome-wide significance level. This approximate conditional analysis is based on the 
summary meta-analysis statistics obtained under a fixed-effects model and takes into 
account the correlations among SNPs, that are estimated from a large reference population 
included in the meta-analysis. Approximate conditional analysis was only carried out in the 
European-ancestry ethnic group which can be assumed to share a similar LD pattern and 
represents the largest ancestry-specific dataset and the only one to show genome-wide 
significant results. As this analysis assumes no heterogeneity in SNP effect size across 
studies, the 9p24.1 and 17q12–21 loci, that show significant heterogeneity (Phet≤0.05 based 
on the Cochran’s Q test) for a large portion of each locus, were not investigated. However, 
for the 17q12–21 locus, where there is no heterogeneity in the pediatric sub-group, GCTA 
was restricted to the European-ancestry pediatric sub-group. We used the large ECRHS 
(European Community Respiratory Health Survey) dataset as the reference sample to 
estimate LD. This dataset was genotyped using Illumina Human610Quad array and included 
2,101 unrelated individuals after QC22. Imputation was done using the MACH software45 
and HapMap2, release 21 panel; only well-imputed SNPs (imputation quality score rsq>0.8) 
and with minor allele frequency (MAF) ≥1% were kept in this reference panel. For each 
asthma-associated locus, the region explored by conditional analysis extended by 500 kb on 
each side of the two extreme SNPs defining the support interval around the lead SNP (see 
preceding paragraph). However, we reduced that extension to 250 kb for the 6p21.33 and 
6p21.32 loci to avoid overlap. The length of the regions explored by conditional analysis 
varied from 1.01 Mb to 1.63 Mb. Within each investigated region by conditional analysis, 
fixed-effects summary meta-analysis data for SNPs belonging to that region were adjusted 
for the lead SNP using the --cojo-cond option; tests for the adjusted SNP effects were based 
on the Wald test If there was an additional SNP meeting the Bonferroni-corrected threshold 
for the total number of SNPs overall all regions investigated by GCTA (P=4.1×10−6) after 
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adjustment for the lead SNP, we performed an additional round including both SNPs. If the 
remaining SNPs had P-values greater than 4.1×10−6, no further analysis was performed. The 
results of this analysis are reported in Supplementary Table 15.
Identification of cis-eQTLs at new asthma risk loci
To get greater insight into the potential genes driving the association signals at the novel 
asthma loci, we defined a list of SNPs to be interrogated that included the lead SNPs, the 
secondary signals identified by conditional analysis and all SNPs in LD with these SNPs (r2 
comprised between 0.5 and 1). To search for cis-expression quantitative trait loci (eQTLs) 
within at most 1 Mb of each investigated SNP, we interrogated six publically available eQTL 
databases by giving priority to cell types more likely to be involved in asthma biology (blood 
cell types and lung tissue): (i) a meta-analysis of the transcriptional profiles from peripheral 
blood cells of 5,311 European-ancestry subjects (the blood eQTL browser11); (ii) the gene 
expression data of 777 lymphoblastoïd cell lines (LCLs) from the MuTHER database10; (iii) 
the transcription profiles of 405 and 550 lymphoblastoïd cell lines from UK asthma 
(MRCA) and eczema (MRCE) family members, respectively13; (iv) the eQTL data from 
monocytes of 1,490, subjects included in the GH-express database23; (v) the GTEx eQTL 
Browser with data from multiple tissues including blood and lung12; (vi) the transcriptional 
profiles from lung tissues of 1,111 subjects14 (see URLs).
Search for missense variants at new asthma risk loci
To complement the eQTL analysis, we searched whether the lead asthma-associated SNPs 
and secondary signals were in LD (r2>0.5) with missense variants using the HaploReg v4.1 
tool (see URLs).
Overlap of loci associated with asthma and other phenotypes
Overlap of novel asthma risk loci with associations with allergy-related phenotypes/diseases 
and immune-related diseases as well as lung function phenotypes was first annotated using 
the March 24, 2015 version of the NHGRI-EBI (National Human Genome Research 
Institute and European Bioinformatics Institute) GWAS catalog3 (see URLs) We then used 
this catalog to systematically investigate the overlap of asthma signals having Prandom ≤ 10−4 
in the multi-ancestry meta-analysis with association signals of all diseases and traits in the 
catalog. That version of the catalog had 19,080 SNP entries, and 16,047 of those SNPs had a 
TAGC asthma association P-value. To investigate pleiotropy, we filtered out SNPs associated 
with asthma in the database, SNPs that have a reported GWAS P-value larger than 10−7 
(with the intent of removing some of the potential false positives in the catalog) and SNPs 
that are duplicated (i.e., remove disease-SNP duplications). This reduced the number of 
entries to 5,927. Note that this process did not remove SNPs in perfect LD associated with 
the same disease, nor SNPs that were present multiple times in the database as associated 
with different phenotypes. For some diseases or quantitative traits, there were multiple SNPs 
in the same region reported in the catalog potentially yielding redundant information. Some 
of the SNPs could be in strong LD, but some could reflect independent signals. To avoid 
possible duplication of signals, we decided to keep only unique trait-loci combinations as 
reflected by the variables "Disease.Trait" and "Region" in the catalog. There were 4,231 
unique entries left after this filtering step. Diseases/traits in the GWAS catalog were grouped 
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using the classification from Wang et al.37 We summarized the overlap of GWAS catalog 
signals with asthma signals by the proportion of catalog SNPs with asthma P-values smaller 
than 10−4 in our analysis. The significance of overlap was estimated by the binomial tail 
probability for observing the number of TAGC SNPs with Prandom≤10−4 among the number 
of SNPs reported in the GWAS catalog for a group of diseases. The significance threshold 
for enrichment in shared associations between a disease group and asthma was set equal to 
0.05 divided by the number of disease groups investigated using a Bonferroni correction. 
Finally, we examined a larger set of SNPs in the GWAS catalog that show an association 
with asthma at Prandom≤10−3 in TAGC multi-ancestry meta-analysis and estimated the 
proportion of false positives among those SNPs.
Enrichment of asthma risk loci in epigenetic marks
To get greater insight into the functional role of the genetic variants at the novel and known 
asthma loci identified by this study, we investigated whether the lead SNPs and their proxies 
(r2≥0.80) were concentrated in cis-regulatory DNA elements. We used the Uncovering 
Enrichment through Simulation pipeline40 (se URLs) that was adapted to the current study. 
This approach tests if GWAS-identified SNPs are enriched in particular functional 
annotations through use of Monte Carlo simulations. The original set of asthma-associated 
SNPs included the lead SNPs at each asthma risk locus (ie one SNP per asthma-associated 
locus, as recommended by Hayes et al40). We excluded the two associated loci that span the 
HLA region (6p21.33 and 6p21.32) because of the high amount of variability and LD in this 
region. Each of the original lead SNPs is categorized by its distance from the nearest 
transcription start site (TSS) and number of LD partners (r2≥0.8). Quartiles for both the TSS 
distance and LD partner count are calculated and the initial SNPs are binned accordingly. 
Then, SNPs from the whole set of imputed SNPs used for analysis are binned according to 
the original SNP criteria (distance from the closest TSS, number of LD partners, and also 
MAF). Random SNP sets are chosen, matching to the original bin frequencies. LD partners 
(r2≥0.8) for both the original lead SNPs and random SNPs are retrieved. The SNP data, 
including the original and random sets of SNPs and their corresponding LD partners 
(r2≥0.8), are intersected with the cell-specific epigenome tracks of regulatory elements using 
the BedTool’s intersectBed46, to determine which SNPs co-localize with a given type of 
regulatory elements (for example, enhancers or promoters). Those resultant SNPs are then 
collapsed into loci that co-localize with marks based on LD structure. We computed an 
empirical-P value for a specific track using 10,000 random SNP sets (this P-value is equal to 
rloci/n where rloci is the number of instances when the frequency of co-localization of the 
random SNP sets with the regulatory feature is greater than or equal to the frequency of co-
localization with the feature for the original SNP set and n is the number of random SNP 
sets generated (here, 10,000). We used the Benjamini-Hochberg false discovery rates (FDR) 
to correct for multiple testing. We interrogated the functional data from 111 ROADMAP 
reference epigenomes and 16 additional epigenomes from ENCODE (Encyclopedia of DNA 
elements) that are available in a wide range of human cell and tissue types24 (see URLs). We 
focused on enhancers and promoters that were defined using the ChromHMM 15-state 
model assayed in all 127 epigenomes. We also examined enrichment in DNase I 
hypersensitivity sites that are available in 51 cell types.
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Connectivity between asthma-associated loci
We used GRAIL (Gene Relationships Across Implicated Loci)25 to assess the relatedness 
between asthma associated loci. As described in detail previously25, to define the genes near 
each SNP, GRAIL finds the furthest neighboring SNPs in the 3′ and 5′ direction that are in 
LD (r2>0.5) and proceeds outward in each direction to the nearest recombination hotspot. 
All genes that overlap that interval are considered implicated by the SNP. If there are no 
genes in that region, the interval is extended by 250 kb in either direction. We took the 
genome-wide significant signals identified by this study as a seed and queried loci to 
investigate biological connectivity among those loci. The connectivity between genes 
belonging to these loci was assessed through text-mining of PubMed abstracts. Each gene at 
each locus was scored for enrichment in GRAIL connectivity to genes located at the other 
loci by using statistical text-mining methods, as previously described25. The 
interconnectivity among genes at asthma risk loci was visualized using VIZGRAIL47 (see 
URLs).
Variance explained by the asthma associated genetic variants
We estimated the variance in liability to asthma explained by the 22 distinct genome-wide 
significant SNPs (18 lead SNPs plus four secondary signals identified by approximate 
conditional analysis) at the 18 asthma-associated loci using a method based on the liability 
threshold model48 and assuming a prevalence of asthma of 10%. The variance in liability to 
asthma explained by individual SNPs was summed over all 22 significant variants. For the 
loci that included two SNPs (lead SNP and secondary signal), we used the SNP effect sizes 
estimated by approximate joint analysis using GCTA44. We also estimated the variance in 
liability to asthma explained by the nine lead SNPs at the nine new asthma loci and by the 
13 distinct genome-wide significant signals at the nine known loci.
Data availability statement
The summary statistics of the meta-analysis that support the findings of this study are 
available through a link from the GWAS Catalog entry for the TAGC study on the EMBL-
EBI (European Bioinformatics Institute) web site (https://www.ebi.ac.uk/gwas/downloads/
summary-statistics).
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Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Manhattan plots of the results of European-ancestry and multi-ancestry random-effects 
meta-analyses of asthma risk. (a) The European-ancestry meta-analysis pertains to 19,954 
cases and 107,715 controls. (b) The multi-ancestry meta-analysis pertains to 23,948 cases 
and 118,538 controls. Each locus is annotated by its cytogenetic band location. The × axis 
represents chromosomal location and the y axis represents −log10 (P value) for tests of 
association between SNPs and asthma. Black, previously known loci; red, new loci 
identified in the European-ancestry meta-analysis; blue, additional new loci identified in the 
multi-ancestry meta-analysis The dashed horizontal line denotes P=5×10−8.
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Figure 2. 
GRAIL25 circle plot of connectivity between genes at asthma risk loci. The 17 asthma risk 
loci are along the outer ring (the 10p14 locus was ignored because it corresponds to a gene 
desert); the internal ring represents the genes at these loci. The width of the lines drawn 
between genes corresponds to the strength of the literature-based connectivity, with thicker 
lines representing stronger connections.
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Table 2
Main characteristics of the nine loci harboring novel associations with asthma
Locusa Location of lead SNPb Cis-eQTLs in blood (B)
and lung tissue (L)
Association with allergy-
related
and lung function 
phenotypes
Association with auto-immune 
diseases
and other immune-related 
traits
New asthma susceptibility loci
5q31.3 NDFIP1 (intron) B: NDFIP1 (2.7×10−9) IBD
6p22.1 Intergenic
B: ZSCAN12 (3.0×10−8)
Lung function
L: ZSCAN31 (6.5×10−11)
6q15 BACH2 (intron) B: BACH2 (3.0×10−10) MS, T1D, CD, IBD, V, IGG
12q13.3 STAT6 (intron)
B: STAT6 (9.8×10−198) IgE (total, specific)
Pso, ISP_IFN
L: STAT6 (3.7×10−37) Lung function
17q21.33 Intergenic B: GNGT2 (2.1×10−52) Atopic dermatitis ISP_IL2
New asthma signals at loci previously associated with asthma in ancestry-specific populations
6p21.33 MICB (intron)
B: TNF (4.8×10−14), LST1 
(1.0×10−13), HLA-C (3.2×10−13), 
LTA (1.0×10−10)
IgE (total, specific), Self-
reported allergy, Atopic 
dermatitis, Lung Function
SLE, UC, RA, IBD, BS, GD, SS, 
AS, Pso, UC, V, WBC, MoC, DS, 
HIV-1, SJS, HB, HBV, IMN, 
CD4:CD8 ratio, HIV-1CL: MICB (4.6×10−13)
10p14 Intergenic None Self-reported allergy RA, ISP_IL1B, ISPV
Asthma signals previously reported for asthma plus hay fever
8q21.13 Intergenic None Atopic dermatitis, Asthma + 
hay fever Self-reported 
allergy
RA
16p13.13 CLEC16A (intron) B: DEXI (2.2×10−43) Atopic dermatitis, Asthma + 
hay fever
T1D, PBC, MS, RA, IBD, CD, 
LEP
At each of the nine loci harboring novel associations with asthma, cis-genes whose expression (e-QTLs) is associated with the lead asthma-
associated SNPs (shown in Table 1) or SNPs in LD (r2≥0.5) with the lead SNPs were searched using six eQTL databases from whole blood11,12, 
lymphoblastoïd cell lines10,13, monocytes23 and lung12,14; only genes with the strongest associations (P-value <5×10−8, as shown in 
parentheses) are presented here (Supplementary Table 16 for details). Overlap of these nine loci with associations with allergy-related and lung 
function phenotypes as well as with auto-immune diseases and other immune-related traits was annotated using the GWAS catalog3;
IBD=Inflammatory bowel diseases (Crohn’s disease), MS=multiple sclerosis, T1D=type 1 diabetes, CD=celiac disease, V=vitiligo, IGG=IgG 
Glycosylation, Pso=psoriasis, ISP_IFN=Immune Response to Smallpox (secreted IFN-alpha), ISP_IL2 Immune Response to Smallpox (secreted 
IL2), SLE=Systemic Lupus Erythematosus, UC=Ulcerative colitis, RA=Rheumatoid arthritis, BS=Behçet syndrome, GD=Grave’s disease, 
SS=Systemic sclerosis, AS=Ankylosing spondylitis, WBC=White Blood cell count, MoC=monocyte count, DS=Dengue shock, HIV-1=HIV-1-
susceptibility, SJS=Stevens-Johnson syndrome, HB=Hepatitis B infection, HBV=Hepatitis B vaccine response, IMN=Idiopathic membranous 
nephropathy, CD4:CD8=CD4:CD8 lymphocyte ratio, HIV-1C= HIV-1 control, ISP_IL1B=Immune Response to Smallpox (secreted IL-1 beta), 
ISPV=Immune response to smallpox vaccine (IL-6), PBC=Primary biliary cirrhosis, LEP=Leprosy.
aCytogenetic band;
b
The protein coding genes flanking intergenic SNPs are shown in Table 1.
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Table 3
Overlap of TAGC asthma-associated SNPs with GWAS catalog association signals by disease group
Disease Group Number of GWAS
catalog association
signals
Number of SNPs
associated with asthma at
Prandom≤10−4 in the multi-
ancestry meta-analysis
P-value for overlap
Cardiovascular 743 20 7.8 × 10−42
Body size and morphology 346 2 5.0 × 10−4
Immune/Autoimmune 480 49 3.0 × 10−129
Nervous system 242 4 1.4 × 10−8
Blood 594 10 1.3 × 10−19
Neuropsychiatric 114 5 1.5 × 10−12
Cancer 417 7 4.0 × 10−14
Endocrine system 276 2 4.0 × 10−4
Digestive system 347 16 1.4 × 10−37
Eyes 177 2 2.0 × 10−4
Respiratory system 85 2 3.6 × 10−5
Infectious disease/Infection 104 2 5.3 × 10−5
Urinary system 144 1 1.5 × 10−2
Alcohol, smoking, and illicit substances 30 0 1
Musculoskeletal system 132 0 1
Overlap of TAGC asthma-associated SNPs with association signals of all diseases/traits in the GWAS catalog3 was investigated for all TAGC SNPs 
having Prandom≤10−4 in the multi-ancestry meta-analysis; diseases from the GWAS catalog were grouped according to the disease classification 
proposed by Wang et al.37 (note that the “Digestive system” group includes Crohn's Disease, a subtype of Inflammatory Bowel Disease). The 
significance of overlap was estimated by the binomial tail probability for observing the shown number of TAGC asthma SNPs among the number 
of SNPs reported in the GWAS catalog for a group of diseases (for example, the probability of observing 20 or more asthma SNPs with 
Prandom≤10−4 among the 743 cardiovascular SNPs is shown in the last column); a conservative Bonferroni adjusted significance threshold for 
enrichment in shared associations is 0.05/15=0.003 (for the 15 disease groups investigated).
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Table 4
Enrichment of asthma risk loci in promoter and enhancer marks and DNase I-hypersensitive sites
Type of regulatory elements Proportion of all cell types (blood cell types) showing
enrichment with a given false discover rate (FDR)
FDR ≤ 10% FDR ≤ 5%
All promoter states 6% (26%) 0
Active promoter states 13% (33%) 0
All enhancer states 57%(100%) 44%(89%)
Active enhancer states 66% (100%) 50%(100%)
DNase I-hypersensitive sites 16% (50%) 12%(40%)
The co-localization of SNPs at asthma risk loci with regulatory elements (promoters, enhancers, DNase I-hypersensitive sites) was assessed at 16 
asthma-loci identified by this study ( Table 1); the 6p21.33 and 6p21.32 loci that encompass the HLA region were excluded because of the high 
amount of variability and LD in this region. Enhancer and promoter states were defined using the ChromHMM 15-state model applied to functional 
data of 127 ROADMAP and ENCODE reference epigenomes in various cell types (including 27 leukocytes)24. DNase I hypersensitivity sites were 
identified in 51 cell types (including 10 leukocytes)24. Empirical-P-values for enrichment were obtained using 10,000 Monte-Carlo simulations of 
random sets of SNPs matching the original set of asthma-associated SNPs40; Benjamini-Hochberg’s FDR was calculated to correct for multiple 
testing (Online Methods for details).
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